#United Kingdom #Edinburgh #Cancer Diagnostics #Wobble Genomics #HER2 profiling

Wobble Genomics Presents New Findings at SABCS 2025

Wobble Genomics is set to make a significant impact at the San Antonio Breast Cancer Symposium (SABCS) 2025 by unveiling groundbreaking findings that enhance understanding of HER2 status in breast cancer. This biotechnology company aims to improve the diagnosis and selection of therapies for cancer patients, and its latest data is poised to advance these objectives further.

Taking place from December 9-12 in San Antonio, Texas, the SABCS is a premier platform for sharing cutting-edge research in breast cancer. Wobble Genomics will present its new data that demonstrates a remarkable capability: accurately detecting HER2 expression, an important biomarker for breast cancer, both from solid tumor biopsies and blood samples. This dual approach signifies a leap in the precision of cancer diagnostics, allowing for a more refined understanding of tumor biology.

The findings confirm that Wobble Genomics' platform can determine HER2 status with impressive fidelity. Specifically, it can deliver detailed isoform-level profiles of HER2 expression, correlating closely with established HER2 immunohistochemistry (IHC) scores. This correlation is vital for clinicians as it provides a clearer picture of the HER2 landscape within a patient's tumor, facilitating more informed treatment decisions.

A key innovation from Wobble Genomics is its long-read RNA technology, which extends its capabilities into blood-based diagnostics. With this technology, the company is not only focusing on direct tumor samples but also exploring non-invasive methods to guide targeted therapy selections based on HER2 status. This approach could revolutionize how treatment plans are formulated, as it grants access to crucial genetic information without the need for invasive procedures.

Dr. Richard Kuo, the CEO and founder of Wobble Genomics, has expressed enthusiasm about the company's breakthrough. He stated, "Our research highlights the significant promise of our platform, offering a new level of precision in cancer diagnostics by providing detailed isoform-level insights into HER2 expression. These findings could enable clinicians to make more informed therapy choices, leading to safer, more personalized care for patients."

The poster presentation scheduled for December 11 is entitled Isoform Level RNA Detection Provides More Detailed Profiling of HER2 Expression in Breast Cancer. This session, set for 5:00 PM to 6:30 PM, will feature contributions from a diverse team of researchers, including Jacob Bradley, Yuanyuan Cheng, and Amy Robinson, among others.

Wobble Genomics has positioned itself as a pioneer in the field of liquid biopsy diagnostics, aiming to refine cancer treatment through superior accuracy. Founded by Dr. Kuo at The Roslin Institute in Edinburgh, Scotland, the company partners with the UK's National Health Service (NHS) to conduct clinical studies that could lead to new standards in oncological care.

In summary, Wobble Genomics is at the forefront of breast cancer diagnostics, showcasing the potential of advanced technologies to alter the treatment landscape. The upcoming presentation at SABCS 2025 promises to shed light on vital new strategies for HER2 profiling, ultimately enhancing the precision of breast cancer therapy decisions for patients around the world.

For further information, you can explore Wobble Genomics on their official website or follow them on professional networks such as LinkedIn.